ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,424,309 | -12.0% | 163,018 | -0.3% | 0.02% | -4.8% |
| Q2 2023 | $5,025,898 | -18.8% | 163,497 | -4.8% | 0.02% | -25.0% |
| Q1 2023 | $6,190,242 | +17.0% | 171,808 | +28.4% | 0.03% | +7.7% |
| Q4 2022 | $5,290,781 | -5.0% | 133,811 | -3.5% | 0.03% | -7.1% |
| Q3 2022 | $5,571,000 | -0.4% | 138,670 | +4.2% | 0.03% | +7.7% |
| Q2 2022 | $5,593,000 | +5.4% | 133,042 | -2.3% | 0.03% | +23.8% |
| Q1 2022 | $5,304,000 | -7.4% | 136,141 | -5.0% | 0.02% | +5.0% |
| Q4 2021 | $5,726,000 | +117.2% | 143,361 | +96.5% | 0.02% | +100.0% |
| Q3 2021 | $2,636,000 | -17.3% | 72,953 | -6.2% | 0.01% | -16.7% |
| Q2 2021 | $3,187,000 | -9.4% | 77,751 | -3.6% | 0.01% | -14.3% |
| Q1 2021 | $3,519,000 | +27.6% | 80,686 | +45.1% | 0.01% | +27.3% |
| Q4 2020 | $2,758,000 | – | 55,619 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |